/IRTC
IRTC Stock - iRhythm Technologies, Inc.
Healthcare|Medical - DevicesNASDAQ
$174.17+3.38%
+$5.69 (+3.38%) • Dec 19
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.70
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).96
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.76
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+23.0%upside
Target: $214.23
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IRTC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$172.43 – $175.91
TARGET (TP)$214.25
STOP LOSS$160.24
RISK/REWARD1:2.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.10
52W High$212.00
52W Low$86.19
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $591.84M | $492.68M | $410.92M | $322.82M | $265.17M |
| Gross Profit | $407.53M | $331.81M | $281.63M | $213.57M | $194.89M |
| Gross Margin | 68.9% | 67.3% | 68.5% | 66.2% | 73.5% |
| Operating Income | $-115,505,000 | $-125,161,000 | $-113,784,000 | $-99,943,000 | $-43,673,000 |
| Net Income | $-113,289,000 | $-123,406,000 | $-116,155,000 | $-101,361,000 | $-43,830,000 |
| Net Margin | -19.1% | -25.0% | -28.3% | -31.4% | -16.5% |
| EPS | $-3.63 | $-4.04 | $-3.88 | $-3.46 | $-1.58 |
Company Overview
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
50%
Hold / Neutral
3
38%
Sell / Underperform
1
13%
Analyst Consensus🟡 Mixed
4 Bullish4 Neutral/Bearish
Price Targets
$131
Average Target
↓ 24.6% Downside
Now
$78
Low
$131
Average
$200
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 23rd 2025 | Evercore ISI | Initiation | In-line | $185 |
| August 20th 2025 | BofA Securities | Initiation | Buy | $200 |
| May 2nd 2025 | Wells Fargo | Upgrade | Overweight | $130 |
| December 3rd 2024 | Wells Fargo | Resumed | Equal Weight | $86 |
| October 4th 2024 | Goldman | Initiation | Neutral | $78 |
| June 20th 2024 | Wolfe Research | Upgrade | Outperform | $115 |
| December 11th 2023 | Citigroup | Upgrade | Buy | $110 |
| July 19th 2023 | Robert W. Baird | Initiation | Outperform | $130 |
| February 7th 2023 | Wells Fargo | Initiation | Overweight | $150 |
| November 7th 2022 | Wolfe Research | Upgrade | Peer Perform | - |
| June 9th 2022 | Citigroup | Downgrade | Neutral | $155← $180 |
| April 6th 2022 | Wolfe Research | Initiation | Underperform | $105 |
Earnings History & Surprises
IRTCBeat Rate
61%
Last 18 quarters
Avg Surprise
+1.0%
EPS vs Estimate
Beats / Misses
11/7
Last 12 quarters
Latest EPS
$-0.06
Q4 2025
EPS Surprise History
Q1 24
-110.0%
$-1.26vs$-0.60
Q2 24
-48.5%
$-1.47vs$-0.99
Q3 24
+33.7%
$-0.61vs$-0.92
Q4 24
-129.1%
$-1.26vs$-0.55
Q1 25
+103.4%
$0.01vs$-0.29
Q2 25
-6.7%
$-0.95vs$-0.89
Q3 25
+39.6%
$-0.32vs$-0.53
Q4 25
+83.3%
$-0.06vs$-0.36
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $0.02 | — | — | — |
Q4 2025 | Oct 30, 2025 | $-0.36 | $-0.06 | +83.3% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $-0.53 | $-0.32 | +39.6% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-0.89 | $-0.95 | -6.7% | ✗ MISS |
Q1 2025 | Feb 20, 2025 | $-0.29 | $0.01 | +103.4% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $-0.55 | $-1.26 | -129.1% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.92 | $-0.61 | +33.7% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.99 | $-1.47 | -48.5% | ✗ MISS |
Q1 2024 | Feb 22, 2024 | $-0.60 | $-1.26 | -110.0% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.65 | $-0.89 | -36.9% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.75 | $-0.61 | +18.7% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.80 | $-1.29 | -61.2% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-0.63 | $-0.67 | -6.3% | ✗ MISS |
Q4 2022 | Nov 1, 2022 | $-0.82 | $-0.63 | +23.2% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.94 | $-0.79 | +16.0% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-1.06 | $-0.80 | +24.5% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $-1.22 | $-1.10 | +9.8% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-1.09 | $-0.81 | +25.7% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.97 | $-0.59 | +39.2% | ✓ BEAT |
Latest News
Truist Securities Maintains Buy on iRhythm Technologies, Lowers Price Target to $215
📈 PositiveBenzinga•Dec 18, 2025, 04:14 PM
Morgan Stanley Maintains Overweight on iRhythm Technologies, Raises Price Target to $205
📈 PositiveBenzinga•Dec 2, 2025, 05:45 PM
iRhythm Technologies Presents Large-Scale Data At APHRS/JHRS Showing Consistent Zio ECG Monitoring Performance Across Asian And Non-Asian Populations
📈 PositiveBenzinga•Nov 21, 2025, 01:14 PM
iRhythm Technologies Announces The Publication Of "Relationship Of Symptom Frequency And Symptom-Rhythm Correlation To Arrhythmia Type And Time To Detection: Insights From Ambulatory ECG Monitoring In Over 1 Million Patients," In The Journal Of The Heart Rhythm Society
➖ NeutralBenzinga•Nov 11, 2025, 01:10 PM
Canaccord Genuity Maintains Buy on iRhythm Technologies, Raises Price Target to $212
📈 PositiveBenzinga•Oct 31, 2025, 08:34 PM•Also:
Citigroup Maintains Buy on iRhythm Technologies, Raises Price Target to $242
📈 PositiveBenzinga•Oct 31, 2025, 08:06 PM•Also:
JP Morgan Maintains Overweight on iRhythm Technologies, Raises Price Target to $240
📈 PositiveBenzinga•Oct 31, 2025, 06:41 PM
Goldman Sachs Maintains Neutral on iRhythm Technologies, Raises Price Target to $202
➖ NeutralBenzinga•Oct 31, 2025, 06:04 PM
iRhythm Technologies shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates. Also, Needham and BTIG raised their respective price targets on the stock.
📈 PositiveBenzinga•Oct 31, 2025, 12:59 PM
Needham Maintains Buy on iRhythm Technologies, Raises Price Target to $244
📈 PositiveBenzinga•Oct 31, 2025, 10:01 AM
BTIG Maintains Buy on iRhythm Technologies, Raises Price Target to $215
📈 PositiveBenzinga•Oct 31, 2025, 08:41 AM
iRhythm Technologies Non-GAAP EPS of -$0.06 beats by $0.22, revenue of $192.9M beats by $8.16M
📈 PositiveSeeking Alpha•Oct 30, 2025, 08:49 PM
iRhythm Technologies shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.
📈 PositiveBenzinga•Oct 30, 2025, 08:38 PM
iRhythm Technologies Raises FY2025 Sales Guidance from $720.000M-$730.000M to $735.000M-$740.000M vs $726.419M Est
📈 PositiveBenzinga•Oct 30, 2025, 08:07 PM
iRhythm Technologies Q3 Adj. EPS $(0.06) Beats $(0.31) Estimate, Sales $192.884M Beat $184.742M Estimate
📈 PositiveBenzinga•Oct 30, 2025, 08:07 PM
Truist Securities Maintains Buy on iRhythm Technologies, Raises Price Target to $205
📈 PositiveBenzinga•Oct 15, 2025, 03:21 PM
BTIG Maintains Buy on iRhythm Technologies, Raises Price Target to $195
📈 PositiveBenzinga•Oct 13, 2025, 12:41 PM
Baird Maintains Outperform on iRhythm Technologies, Raises Price Target to $220
📈 PositiveBenzinga•Oct 10, 2025, 02:46 PM
Citigroup Maintains Buy on iRhythm Technologies, Raises Price Target to $205
📈 PositiveBenzinga•Oct 7, 2025, 05:43 PM•Also:
Evercore ISI Group Maintains In-Line on iRhythm Technologies, Lowers Price Target to $175
➖ NeutralBenzinga•Oct 7, 2025, 05:38 PM
Frequently Asked Questions about IRTC
What is IRTC's current stock price?
iRhythm Technologies, Inc. (IRTC) is currently trading at $174.17 per share. The stock has moved +3.38% today.
What is the analyst price target for IRTC?
The average analyst price target for IRTC is $214.25, based on 1 analyst.
What sector is iRhythm Technologies, Inc. in?
iRhythm Technologies, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is IRTC's market cap?
iRhythm Technologies, Inc. has a market capitalization of $5.61 billion, making it a mid-cap company.
Does IRTC pay dividends?
No, iRhythm Technologies, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARWR
Arrowhead Pharmaceuticals, Inc.
$68.16
Mkt Cap: $9.4B
BLCO
Bausch + Lomb Corporation
$16.98
Mkt Cap: $6.0B
BRKR
Bruker Corporation
$46.48
Mkt Cap: $7.1B
BTSG
BrightSpring Health Services, Inc. Common Stock
$37.49
Mkt Cap: $6.8B
CHE
Chemed Corporation
$435.33
Mkt Cap: $6.4B
CRSP
CRISPR Therapeutics AG
$55.86
Mkt Cap: $4.9B
GKOS
Glaukos Corporation
$116.22
Mkt Cap: $6.7B
PCVX
Vaxcyte, Inc.
$46.42
Mkt Cap: $6.1B
RDNT
RadNet, Inc.
$76.68
Mkt Cap: $5.9B
TFX
Teleflex Incorporated
$121.89
Mkt Cap: $5.4B
Explore stocks similar to IRTC for comparison